Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 11/20 | 0.63 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.47 |
| ▸ | F12 | P00748 | 3/20 | 0.45 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16140457 | 0.92 | BAZ2B (0.71) | BAZ2BNR1H2LMNAPABPC1ATM | |
| SCHEMBL6474229 | 0.86 | BAZ2B (0.63) | BAZ2BLMNAPABPC1ATMSMN1; SMN2 | |
| SCHEMBL6474214 | 0.83 | LMNA (0.60) | BAZ2BLMNATRPV1 | |
| SCHEMBL5362823 | 0.83 | BAZ2B (0.66) | BAZ2BLMNAPABPC1ATMSMN1; SMN2 | |
| SCHEMBL6483420 | 0.81 | BAZ2B (0.45) | BAZ2BNR1H2LMNAPABPC1ATM | |
| SCHEMBL6481513 | 0.81 | BAZ2B (0.46) | BAZ2BLMNAPABPC1ATMSMN1; SMN2 | |
| SCHEMBL25420584 | 0.81 | ESR2 (0.52) | BAZ2BLMNAPABPC1ATMSMN1; SMN2 | |
| SCHEMBL6196157 | 0.80 | HTR6 (0.53) | BAZ2BLMNAPABPC1ATMSMN1; SMN2 | |
| SCHEMBL2832897 | 0.80 | LMNA (0.76) | BAZ2BLMNAPABPC1ATMSMN1; SMN2 | |
| SCHEMBL30228387 | 0.80 | TRPV1 (0.59) | BAZ2BLMNAPABPC1ATMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291738-B2 | Therapeutic compounds | PHARMACIA & UPJOHN COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291738-B2 | Therapeutic compounds | PHARMACIA & UPJOHN COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-20030181485-A1 | A (2-methyl-3-pyridinyl)oxy)-3-pyridinyl)urea derivatives for treatment of a disease or disorder of the central nervous system, medical diagnosis | PHARMACIA & UPJOHN COMPANY | 2003-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181485-A1 | A (2-methyl-3-pyridinyl)oxy)-3-pyridinyl)urea derivatives for treatment of a disease or disorder of the central nervous system, medical diagnosis | PMP22, TPMT, PNPO | BAZ2B 3345/4885NR1H2 1446/4885LMNA 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.